PrxII Inhibitor Reduces Colorectal Polyps via β-catenin Degradation
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current treatments for colorectal cancer (CRC) are limited in effectively addressing the metastasis and polyp formation associated with APC gene mutations, particularly due to the lack of targeted mechanisms for regulating peroxiredoxin 2 (PrxII) activity and its interaction with tankyrase (TNKS), which are crucial in redox system regulation and signal transduction.
Innovation Solution
A pharmaceutical composition that inhibits the enzyme activity of PrxII, characterized by specific compounds (e.g., Compound-1 to Compound-6) that increase β-catenin degradation, decrease Axin1 degradation by TNKS, and enhance oxidative inactivation of TNKS, thereby reducing the interaction between PrxII and TNKS in APC-mutant cells, is developed.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Reliability
If peroxiredoxin 2 (PrxII) activity is inhibited, then colorectal polyp formation and CRC progression are reduced, but the mechanism of action and selectivity must be precisely controlled to avoid off-target effects
Solution Approach 1:
The patent identifies PrxII as a key target and focuses on changing its enzymatic activity parameter through specific inhibitors. By modulating the catalytic activity of PrxII in the redox system, the invention achieves therapeutic efficacy while managing complexity through targeted molecular intervention rather than broad systemic approaches.
Solution Approach 2:
The patent introduces tankyrase (TNKS) as an intermediary protein that interacts with PrxII. By targeting the PrxII-TNKS interaction interface, the invention creates a controlled mechanism where inhibition of PrxII activity specifically disrupts the signaling pathway without affecting other redox processes, thus managing system complexity.
2Reliability
If PrxII activity is inhibited to treat CRC, then metastasis and polyp formation are reduced, but side effects may occur due to PrxII's role in normal redox regulation
Solution Approach 1:
The patent applies local quality by specifically targeting the PrxII-TNKS interaction in the context of APC-mutant cells. The inhibition is localized to the signaling pathway involved in polyp formation and metastasis, while preserving PrxII's general redox regulation function in normal tissues, thus reducing side effects.
Solution Approach 2:
The patent exploits the harmful interaction between PrxII and TNKS in APC-mutant cells (which drives cancer progression) and converts it into a therapeutic benefit. By inhibiting this specific harmful interaction, the invention selectively targets cancer cells without affecting normal physiological redox processes.
3Productivity
If tankyrase (TNKS) interaction with PrxII is decreased, then β-catenin degradation is increased and CRC progression is inhibited, but the specificity of this interaction must be maintained to avoid affecting other signaling pathways
Solution Approach 1:
The patent uses TNKS as an intermediary protein to mediate the effect of PrxII inhibition. By targeting the interaction between PrxII and TNKS, the invention achieves specific control over β-catenin degradation while maintaining precision through the selective disruption of this particular protein-protein interaction interface.
Solution Approach 2:
The patent segments the redox system and signaling pathways by focusing on the specific PrxII-TNKS interaction rather than treating the entire system uniformly. This segmentation allows for precise control over β-catenin degradation while isolating the mechanism from other signaling pathways.
Applied Scientific Principles
This section explains which scientific principles are used to turn an abstract innovation direction into a practical engineering solution.
Function Achieved in This Case
The composition effectively reduces colorectal polyps and treats CRC by regulating the redox system, inhibiting CRC progression, and preventing metastasis by targeting PrxII activity in APC-mutant cells, offering a novel therapeutic approach for CRC management.
Implementation Method 1
the intestinal tumor formation triggered by the APC gene mutation is promoted by the acquisition or inheritance of a mutation in DNA glycosylase, which plays an important role in repair of bases in nucleic acids at the time of oxidative DNA damage. This shows that elevation in the levels of reactive oxygen species (ROS) is involved in the APC mutation-inducible intestinal tumor formation.
Implementation Method 2
PrxII, a 2-Cys Prx enzyme, is thought to play a multifaceted role in intracellular ROS detoxification and signal transduction. The composition effectively reduces colorectal polyps and treats CRC by regulating the redox system, inhibiting CRC progression, and preventing metastasis by targeting PrxII activity
Implementation Method 3
the material inhibiting the enzyme activity of PrxII is characterized by it increases the degradation of β-catenin. In the pharmaceutical composition for treating CRC by the present invention, the material that inhibits the enzyme activity of PrxII is characterized in that it increases the degradation of β-catenin.
Data Source
AI summary
The present invention relates to a pharmaceutical composition for treating colorectal cancer including a material inhibiting the enzyme activity of peroxiredoxin 2 as an active ingredient, and more specifically, to a pharmaceutical composition for treating colorectal cancer, which exhibits the effect of reducing colon polyps via increase of active β-catenin degradation by inhibiting the activity of peroxiredoxin 2, based on the mechanism that promotes colorectal tumor by the interaction between peroxiredoxin 2 (PrxII) and tankyrase (TNKS) in an APC-mutant cell.